These tables are also available in a printable version (PDF, 583 KB).
World Health Organization. International Statistical Classification of Diseases and Related Health problems, Tenth Revision. Geneva: World Health Organization. 2007
Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List.
COMPREHENSIVE ICD-10 Casefinding Code List for Reportable Tumors
ICD-10 Code | Explanation of ICD-10 Code |
---|---|
B21._ | Human Immunodeficiency virus [HIV] disease with malignant neoplasms |
C00._ - C97._ | Malignant neoplasms Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant). |
D00._ - D09._ | In-situ neoplasms Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable. |
D18.0 | Hemangioma, any site Note: Includes Hemangiomas of Brain, Other parts of nervous system and endocrine glands, which are reportable. |
D18.1 | Lymphangioma, any site Note: Includes Lymphangiomas of Brain, Other parts of nervous system and endocrine glands, which are reportable. |
D32._ | Benign neoplasm of meninges (cerebral, spinal and unspecified) |
D33._ | Benign neoplasm of brain and other parts of central nervous system |
D35.2 | Benign neoplasm of pituitary gland |
D35.3 | Benign neoplasm of craniopharyngeal duct |
D35.4 | Benign neoplasm of pineal gland |
D42._ | Neoplasm of uncertain or unknown behavior of meninges |
D43._ | Neoplasm of uncertain or unknown behavior of brain and central nervous system |
D44.3 - D44.5 | Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland |
D45 | Polycythemia vera (9950/3) |
D46._ | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992) |
D47.1 | Chronic myeloproliferative disease (9960/3, 9961/3, 9963/3) |
D47.3 | Esssential (hemorrhagic) thrombocythemia (9962/3) |
D47.7 | Other specified neoplasms of uncertain/unknown behavior of lymphoid, hematopoietic (9965/3, 9966/3, 9967/3, 9971/3, 9975/3, 9987/3) |
D47.9 | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9961/3, 9970/1, 9931/3) |
D48.9 | Neoplasm of uncertain or unknown behavior, unspecified Note: Review code for uncertain behavior brain, CNS tumors and reportable benign endocrine glands |
NOTE: Cases with these codes should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases.
SUPPLEMENTAL LIST ICD-10
ICD-10 Code^ | Explanation of ICD-10 Code* |
---|---|
B20._, B22 - B24 | Human immunodeficiency virus [HIV] disease with other diseases Note: Excludes HIV with malignancy (B21), see reportable list |
B99 | Other infectious diseases (Human papillomavirus, Retrovirus-HTLV types I, II, 2) |
D10._ - D31._, D34, D35.0, D35.1, D35.5 - D35.9, D36._ |
Benign neoplasms (see "must collect" list for reportable benign neoplasms) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER. |
D37._ - D41._ | Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
D44.0 - D44.2, D44.6 - D44.9 |
Neoplasm of uncertain or unknown behavior of other endocrine glands (see "must collect" list for D44.3-D44.5) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
D47.0 | Histiocytic and mast cell tumors of uncertain behavior |
D47.2 | Monoclonal gammopathy Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia |
D48._ | Neoplasms of uncertain or unknown behavior Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
D61.1 | Drug-induced aplastic anemia (also known as “aplastic anemia due to antineoplastic chemotherapy) |
D61.8 | Other specified aplastic anemias (drug induced pancytopenia) Note: screen for blood disorders due to neoplasm |
D64.8 | Other specified anemias Note: Includes anemia due to neoplastic disease or antineoplastic chemotherapy |
D69.4 - D69.6 | Other thrombocytopenia Note: Screen for incorrectly coded thrombocythemia |
D70 | Agranulocytosis (Note: Screen for blood disorders due to neoplasm) |
D72.1 | Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is with a malignancy. Diagnosis must be "Hypereosonophilic syndrome" to be reportable.) |
D75.8 | Other specified diseases of blood and blood-forming organs |
D76._ | Certain diseases involving lymphoreticular tissue and reticulohistiocytic system |
D89.1 | Cryoglobulinemia |
D89.2 | Hypergammaglobulinemia, unspecified Note: screen for blood disorders due to neoplasm |
D89.3 | Immune reconstitution syndrome Note: screen for blood disorders due to neoplasm |
E34.0 | Carcinoid syndrome Note: Part of the paraneoplastic syndrome |
E34.1 | Other hypersecretion of intestinal hormones Note: Part of the paraneoplastic syndrome |
E83.5 | Disorders of calcium metabolism (hypercalcemia) Note: Part of the paraneoplastic syndrome |
E88.0 | Disorders of plasma-protein metabolism, not elsewhere classified Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia |
E88.8 | Other specified metabolic disorders (Tumor lysis syndrome) |
G13.0 | Paraneoplastic neuromyopathy and neuropathy (carcinomatous neuromyopathy) |
G13.1 | Other systemic atrophy primarily affecting central nervous system in neoplastic disease (paraneoplastic limbic encephalopathy) |
G73.1 | Lambert-Eaton syndrome |
G99.2 | Myelopathy in diseases classified elsewhere (underlying disease neoplasm) |
H47.4 | Disorders of optic chiasm |
H47.5 | Disorders of other visual pathways |
H47.6 | Disorders of visual cortex |
J34.8 | Other specified disorders of nose and nasal sinuses |
J91 | Pleural effusion in conditions classified elsewhere |
J93.1 | Other spontaneous pneumothorax |
K12.3 | Oral mucositis (ulcerative) |
K22.7 | Barrett’s esophagus |
K62.7 | Radiation proctitis |
K62.8 | Other specified diseases of anus and rectum (AIN I, AIN II) |
K92.8 | Other specified diseases of digestive system (mucositis due to cancer therapy) |
M36.0 | Dermato(poly)myositis in neoplastic disease |
M36.1 | Arthropathy in neoplastic disease |
M84.4 | Pathological fracture, not elsewhere classified |
M90.6 | Osteitis deformans in neoplastic disease |
N42.8 | Disorder of prostate (PIN I and PIN II) |
N76.8 | Other specified inflammation of vagina and vulva |
N87._ | Dysplasia of cervix (CIN I and CIN II) |
N89.0-N89.3 | Dysplasia of vagina (VAIN I and VAIN II) |
N90.0-N90.3 | Dysplasia of vulva (VIN I and VIN II) |
O01._ | Hydatidiform mole (Note: benign tumor that can become malignant. If malignant, it should be reported as Choriocarcinoma (9100/3) with malignancy code in c00-c97)) |
O90.8 | Other complications of the puerperium, not elsewhere classified |
Q85.0 | Neurofibromatosis (nonmalignant) (9540/1) (Note: Neurofibromatosis by itself is not reportable, but it can lead to a reportable condition) |
R18 | Ascites (malignant) |
R52.9 | Pain, unspecified (neoplasm related pain, cancer associated pain) |
R53 | Malaise and fatigue (neoplasm related fatigue) |
R59._ | Enlarged lymph nodes |
R85.6 | Abnormal findings on cytological/histological exam of digestive organs |
R87.6 | Abnormal findings on cytological/histological exam of female genital organs |
R92 | Abnormal findings on diagnostic imaging of breast |
T38.6 | Poisoning by antigonadotrophins, antiestrogens, and antiandrogens, not elsewhere classified |
T38.8 | Poisoning by other and unspecified hormones and their synthetic subsitutes |
T38.9 | Poisoning by other and unspecified hormone antagonists |
T45.1 | Poisoning by antineoplastic and immunosuppressive drugs |
T45.8 | Poisoning by other primarily systemic and hematologic agents |
T45.9 | Poisoning by other primarily systemic and hematological agent, unspecified |
T66 | Unspecified effects of radiation |
T80.1 | Vascular complications following infusion, transfusion, and therapeutic injection |
T80.2 | Infections following infusion, transfusion, and therapeutic injection |
T80.8 | Other complications following infusion, transfusion and therapeutic injection |
T86.0 | Failure and rejection of transplanted organs and tissues: Bone-marrow transplant rejection |
Y42.1 | Other and unspecified hormone antagonists (poisoning) |
Y42.6 | Adverse reaction to antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified |
Y43.1 - Y43.4 | Adverse effects in therapeutic use, antineoplastic products or drugs |
Y43.9 | Adverse effects in therapeutic use, primarily systemic agent, unspecified Note: Includes poisoning by primarily systemic and hematological agents |
Y63.2 | Failure in dosage, overdose of radiation given during therapy Note: Includes adverse reaction to radiation |
Y84.2 | Abnormal reaction, radiological procedure and radiotherapy (radiation sickness) |
Y84.9 | Other medical procedures (abnormal reactions, complications from central venous catheters) |